BioCentury
ARTICLE | Company News

CGI, Gilead deal

June 28, 2010 7:00 AM UTC

Gilead will acquire CGI (formerly Cellular Genomics Inc.) for up to $120 million in cash. An undisclosed majority of the payment will be paid up front, with the remainder to be paid upon clinical milestones. Gilead said the deal broadens its research into kinase biology and chemistry. CGI has a library of small molecule kinase inhibitors, with a lead preclinical program targeting Syk tyrosine kinase (SYK) for inflammatory diseases, including rheumatoid arthritis (RA). ...